...mutation status of TGFBR2, RHOA, and PREX2 influenced the PFS of immunotherapy...PREX2 p.M627V, p.W519G, p.R1567Q mutations had been identified and the median PFS of patients with PREX2wt and PREX2mt were 5.0 months (95%CI,2.0–8.0 months) and 2.4 months (95%CI, 0.5–4.3 months; p = 0.037), respectively.